Hims stock fell after the U.S. Food and Drug Administration said the shortages in Novo Nordisk's weight-loss drug has been resolved.
Read more at Investor's Business Daily
Shares of Hims & Hers tumble 26% after FDA says semaglutide is ...
The FDA said the shortage of semaglutide injection products such as Novo Nordisk's Ozempic and Wegovy has been resolved. The agency said it will start ...
Read more at CNBC
Hims stock - 10 things to know with detail
Hims & Hers Health, Inc. is a telehealth company that specializes in providing personalized healthcare and wellness products for men and women.
The company went public through a SPAC (special purpose acquisition company) merger with Oaktree Acquisition Corp. in January 2021.
Hims stock trades on the New York Stock Exchange under the ticker symbol "HIMS."
The company offers a range of products and services, including prescription medication, over-the-counter treatments, and telehealth consultations with healthcare professionals.
Hims focuses on treating conditions such as erectile dysfunction, hair loss, skincare issues, and mental health concerns.
The company's revenue primarily comes from the sale of its products and services, as well as subscription-based offerings.
Hims has faced criticism for its marketing tactics, which some have argued promote unnecessary medical treatments and feed into societal pressures around appearance and self-image.
The company has also faced legal challenges related to its marketing practices, including allegations of deceptive advertising.
Hims has experienced significant growth since going public, with its stock price reaching new highs in 2021.
Investors should carefully consider the risks and opportunities associated with investing in Hims stock, including competition in the telehealth industry, regulatory challenges, and potential shifts in consumer behavior.